Prognostic and predictive performance of PREDICT 2.1, PREDICT v3, and RSClin in node-negative early breast cancer: a TEAM pathology substudy

Key Points

• PREDICT 2.1 and RSClin show comparable prognostic performance with node-negative breast cancer outcomes.
• The predictive analysis includes the evaluation of two models and biomarkers relevant to patient treatment.
• Assessment using observational analysis of early breast cancer data reveals significant insights into model effectiveness.
• These findings highlight the need for external validation of predictive performance in diverse cohorts.